Neuphoria Therapeutics amends rights plan, extends expiration to October 2027

Neuphoria Therapeutics Inc. disclosed in an 8-K that on October 23, 2026, its Board of Directors entered into Amendment No. 1 to the Rights Agreement, dated as of October 27, 2025, by and between the Company and Computershare Trust Company, N.A., as Rights Agent¹.

Under the amendment, the Final Expiration Date of the Original Rights Agreement has been extended until the Close of Business on October 27, 2027, unless earlier extended, modified or terminated¹. The filing does not state what the original expiration date was before this amendment.

Neuphoria said the Rights are in all respects subject to and governed by the provisions of the Original Rights Agreement, except as amended by the Amendment¹. The company noted the description of the Original Rights Agreement and the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Rights Agreement, which is incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the U.S. Securities and Exchange Commission on October 27, 2025, and to the Amendment, which is attached hereto as Exhibit 4.2¹.

The filing also stated that the information on the material definitive agreement was incorporated into Item 3.03 covering Material Modifications to Rights of Security Holders¹. The 8-K was signed by Spyridon Papapetropoulos, identified in the filing as Interim Chief Executive Officer¹, dated October 23, 2026.